Skip to main content
. Author manuscript; available in PMC: 2019 Dec 15.
Published in final edited form as: Clin Cancer Res. 2018 Aug 9;24(24):6142–6149. doi: 10.1158/1078-0432.CCR-18-1381

Table 1.

Patient characteristics of 20 patients in phase 2 cohort and 12 patients in oral solution cohort.

Characteristic Phase 2
(n = 20)
Oral Solution
(n = 12)
Median Age (Range), years 10.7 (4.3–19.4) 3.0 (1.6–7.2)
Male : Female 14 : 6 6 : 6
MYCN Amplified : Non-Amplified 3 : 14 6 : 5
Prior Irinotecan 11 (55%) 2 (17%)
Prior Temozolomide 10 (50%) 2 (17%)
Median Number of Prior Regimens (Range) 3 (1–10) 1 (1–2)
> 3 Prior Regimens 8 (40%) 0 (0%)